Citations

Clear

6273 citation(s) found for "To, Andrew".

Impact of smoking on recurrence rates among wide-neck intracranial aneurysms treated with Woven EndoBridge: a multicenter retrospective study
Vaishnav, Dhrumil , Adeeb, Nimer , Aslan, Assala , Cancelliere, Nicole M., McLellan, Rachel , Ghozy, Sherief, Lay, Sovann V. , Guenego, Adrien , Premat, Kévin , Möhlenbruch, Markus, Kral, Michael , Doron, Omer , Salem, Mohamed M. , Foreman, Paul M. , Vachhani, Jay A. , Shaikh, Hamza, Župančić, Vedran , Ayberk, Gıyas , Güneş, Yasin Celal , Rabinov, James D. , Ren, Yifan , Michelozzi, Caterina , Elens, Stéphanie , Starke, Robert M., Hassan, A. , Ogilvie, Mark , Nguyên, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Psychogios, Marios, Ulfert, Christian , Diestro, Jose Danilo Bengzon , Pukenas, Bryan , Burkhardt, Jan‐Karl , Martinez-Gutierrez, Juan Carlos, Sheth, Sunil G. , Spiegel, Gary, Lubicz, Boris , Puri, Ajit S., Pero, Guglielmo , Nossek, Erez , Raz, Eytan, Griessenauer, Christoph J., Asadi, Hamed , Siddiqui, Adnan, Brook, Allan , Haranhalli, Neil , Ducruet, Andrew F. , Albuquerque, Felipe C. , Regenhardt, Robert W. , Stapleton, Christopher J. , Kan, Peter, Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Knopman, Jared , Tjoumakaris, Stavropoula I., Clarençon, Frédéric, Cuellar-Saenz, Hugo H., Patel, Aman B. , Altschul, David , _, _, Spears, Julian , Sundararajan, Sri Hari , Balush, Ali Al, Inoue, Yasuaki , Mirshahi, Shervin , Harker, Pablo, Tutino, Vincent M., Brehm, Alex , Diestro, Jose Danilo B , Shotar, Eimad , Nguyen, Anh , Pero, Guglielmo , Kalousek, Vladimir , Altschul, David J , Regenhardt, Robert W , Ulfert, Christian , Lay, Sovann V , Essibayi, Muhammed Amir , Musmar, Basel , Salim, Hamza , Cancelliere, Nicole M , Algin, Oktay , Ghozy, Sherief , Renieri, Leonardo , Carnevale, Joseph Anthony , Saliou, Guillaume , Mastorakos, Panagiotis , Naamani, Kareem El , Shotar, Eimad , Möhlenbruch, Markus , Chung, Charlotte , Lylyk, Iván , Hafeez, Muhammad Ubaid , Catapano, Joshua S , Waqas, Muhammad , Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna Luisa , Hassan, Ameer E , Psychogios, Marios‐Nikos , Huynh, Thien , Martinez-Gutierrez, Juan Carlos , Sheth, Sunil A., Tawk, Rabih G. , Panni, Pietro , Puri, Ajit S , Raz, Eytan , Killer-Oberpfalzer, Monika , Griessenauer, Christoph J. , Aziz‐Sultan, Mohammad Ali , Tjoumakaris, Stavropoula , Clarençon, Frédéric , Limbucci, Nicola , Cuellar, Hugo , Jabbour, Pascal , Mendes Pereira, Vitor , Dmytriw, Adam A. , _, _, Dibas, Mahmoud , Vranic, Justin E. , Alotaibi, Naif M. , Harker, Pablo , Sporns, Peter Bernhard

Mayo Clinic

Journal of Neurosurgery | January 31, 2025 | Volume: 142 | Issue: 6 | Pages: 1732-1740

10.3171/2024.10.jns241058 | PMID 39889291 Get It

OBJECTIVE Tobacco smoking is among the factors known to significantly augment the risk of untreated intracranial aneurysm (IA) growth and rupture. Smoking appears to have a variable effect on different endovascular treatment modalities. The impact of smoking on the safety, efficacy, and outcomes of Woven EndoBridge (WEB) device use for wide-neck IAs has not been evaluated. This study aimed to investigate the outcomes of WEB devices by smoking status. METHODS A retrospective multicenter analysis was conducted on the data of patients from 36 sites worldwide treated with the WEB device for intracranial saccular aneurysms. Patients were stratified based on smoking status (current, former, and never smokers). The Student t-test and chi-square test were performed for continuous and categorical variables, respectively. Multivariable logistic regression was used to adjust for confounders. RESULTS Of 1376 patients with available smoking status, 504 were current smokers, 358 were former smokers, and 514 were never smokers. Upon adjusting for significant confounders, no association was found between smoking and recurrence outcomes (OR 1.39, 95% CI 0.69–2.80; p = 0.36), thromboembolic and hemorrhagic complications, and mortality among IAs treated with the WEB device. There was no statistically significant difference in outcomes between former and never smokers (OR 1.23, 95% CI 0.70–2.18; p = 0.46). The location of aneurysms differed between smoking groups, with former smokers having more anterior circulation aneurysms compared with current and never smokers (99.0% vs 96.9% vs 95.3%; p = 0.01). In terms of clinical symptoms, headache and dizziness were more common in the never smokers compared with current and former smokers (13.9% vs 8.9% vs 7.7%, p = 0.01). CONCLUSIONS This large-scale study suggests no significant correlation between smoking and the recurrence of IAs treated with the WEB device. Biological studies are warranted to better understand the biological impact of smoking on the growth and rupture of treated IAs.
1406: ACUTE KIDNEY INJURY IN CARE TRANSITIONS (ACT) TRIAL: A POST HOC ANALYSIS OF ICU SURVIVORS
Cole, Kristin, Kattah, Andrea G. , Ledet, Caroline, Tinaglia, Angeliki G. , Frazee, Erin N. , May, Heather P. , Cole, Kristin, Griffin, Joan M. , Herges, Joseph R. , Kashani, Kianoush , Ledet, Caroline, McCoy, Rozalina G. , Rule, Andrew D.

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001104288.83709.4e Get It

986: THE IMPACT OF EXTENDING BETA-LACTAM INFUSIONS ON INTRAVENOUS ACCESS REQUIREMENTS
Kooda, Kirstin , Nelson, Julia, Ausman, Sara , Saleh, Omar Abu , Warfield, Micaela , Zhao, Maggie, Frazee, Erin N. , Nelson, Julia, Ausman, Sara E , Rivera, Christina G. , Rule, Andrew D. , Stevens, Ryan W. , Zhao, Maggie

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001102608.95590.33 Get It

982: EXTERNAL VALIDATION OF THE FRASER EQUATION TO ESTIMATE FREE VALPROATE CONCENTRATION IN THE ICU
Brown, Caitlin S. , Liu, JiTong , Riker, Richard R. , Lopez, Natasha , Gagnon, David J. , Webb, Andrew , Rosenthal, Eric S.

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001102592.08813.34 Get It

Ventral Rectopexy: An International Expert Panel Consensus and Review of Contemporary Literature
Perry, William , Collinson, Rowan , Cornish, Julie , D’Hoore, André , Gurland, Brooke , Mellgren, Anders, Ris, Frédéric , Bordeianou, Liliana , Group, On behalf of the Ventral Rectopexy Working, Perry, William , Perry, William R , Cornish, Julie A , Ris, Frederic , Christensen, Peter , Ratto, Carlo , Stevenson, Andrew R. L. , Group, On behalf of the Ventral Rectopexy Working

Mayo Clinic

Diseases of the Colon & Rectum | January 30, 2025 | Volume: 68 | Issue: 5 | Pages: 593-607

10.1097/dcr.0000000000003656 | PMID 39882786 Get It

BACKGROUND: Ventral rectopexy has become increasingly used in the surgical management of rectal prolapse. There is a need for a contemporary evaluation of the role of the procedure and a description of its use in clinical practice. OBJECTIVE: To create an international consensus on ventral rectopexy. DESIGN: An expert panel undertook a scoping review of the literature to identify subject domains of interest. Literature reviews were completed for each domain with subsequent development of evidence-based and practice-based statements. These statements were compiled and reviewed by the group over a total of 9 meetings. Once statements were confirmed, supportive text was finalized, and an anonymous vote was completed using Research Electronic Data Capture to record consensus. SETTING: An international expert panel comprising colorectal surgeons who perform ventral rectopexy in a high-volume center. MAIN OUTCOME MEASURES: Statements and associated expert consensus. RESULTS: Eleven experts identified 10 domains for review: indications, contraindications, assessment and planning, consent, operative details, prostheses, complications, follow-up, recurrence and reoperative surgery, and specific considerations. After round table review, there were 17 resultant statements for consideration. Experts agreed unanimously with 13 of the statements and their accompanying text, with different experts disagreeing regarding the remaining 4 statements (91% consensus each). LIMITATIONS: Paucity of high-quality data. CONCLUSIONS: This international group developed 17 statements with high consensus. These statements provide an up-to-date summary of the literature, identify key areas for research development, and provide a reference point for colon and rectal surgeons who undertake ventral rectopexy as part of their practice. See Video Abstract . RECTOPEXIA VENTRAL: CONSENSO DE UN PANEL INTERNACIONAL DE EXPERTOS Y REVISIÓN DE LA LITERATURA CONTEMPORÁNEA ANTECEDENTES: La rectopexia ventral se ha utilizado cada vez más en el tratamiento quirúrgico del prolapso rectal. Es necesario realizar una evaluación contemporánea del rol del procedimiento y una descripción de su uso en la práctica clínica. OBJETIVO: Crear un consenso internacional sobre la rectopexia ventral. DISEÑO: Un panel de expertos realizó una revisión exhaustiva de la literatura para identificar los dominios temáticos de interés. Se completaron revisiones de la literatura para cada dominio con el desarrollo de declaraciones basadas en la evidencia y la práctica. Estas fueron compiladas y revisadas por el grupo a lo largo de un total de nueve reuniones. Una vez que se confirmaron las declaraciones, se finalizó el texto de apoyo y se completó una votación anónima utilizando REDCap para registrar el consenso. ESCENARIO: Un panel internacional de expertos compuesto por cirujanos colorrectales que realizan rectopexia ventral en un centro de alto volumen. PRINCIPALES MEDIDAS DE RESULTADOS: Declaraciones y consenso de expertos asociado. RESULTADOS: Once expertos identificaron diez dominios a revisar: indicaciones, contraindicaciones, evaluación y planificación, consentimiento, detalles operatorios, prótesis, complicaciones, seguimiento, recurrencia y cirugía reoperatoria y consideraciones específicas. Después de la revisión en mesa redonda, hubo 17 declaraciones resultantes para su consideración. Los expertos estuvieron de acuerdo unánimemente con trece de las declaraciones y su texto acompañante, y diferentes expertos estuvieron en desacuerdo con cuatro declaraciones (91% de consenso cada una). LIMITACIONES: Escasez de datos de alta calidad. CONCLUSIÓN: Este grupo internacional desarrolló 17 declaraciones con alto consenso. Estas declaraciones proporcionan un resumen actualizado de la literatura, identifican áreas claves para el desarrollo de la investigación y un punto de referencia para los cirujanos de colon y recto que realizan rectopexia ventral como parte de su práctica. (Traducción—Dr. Aurian Garcia Gonzalez )
Improved Outcomes and Resource Use With Normothermic Machine Perfusion in Liver Transplantation
Zhang, Chi , Li, Xingjie , Ohara, Stephanie , Kumm, Kayla , Cosentino, Christopher P., Aqel, Bashar , Frasco, Peter E. , Nunez-Nateras, Raphael, Hewitt, Winston R. , Harbell, Jack W. , Singer, Andrew L., Moss, Adyr A. , Reddy, Kunam S. , Mathur, Amit K. , Kumm, Kayla R, Lizaola-Mayo, Blanca C, Nguyen, Michelle , Chang, Yu‐Hui , Aqel, Bashar A. , Lizaola‐Mayo, Blanca , Nunez-Nateras, Raphael, Katariya, Nitin , Jadlowiec, Caroline C.

Mayo Clinic

JAMA Surgery | January 29, 2025 | Volume: 160 | Issue: 3 | Pages: 322

10.1001/jamasurg.2024.6520 | PMID 39878966 Get It

Importance Normothermic machine perfusion (NMP) has been shown to reduce peritransplant complications. Despite increasing NMP use in liver transplant (LT), there is a scarcity of real-world clinical experience data. Objective To compare LT outcomes between donation after brain death (DBD) and donation after circulatory death (DCD) allografts preserved with NMP or static cold storage (SCS). Design, Setting, and Participants This single-center, retrospective observational cohort study included all consecutive adult LTs performed between January 2019 and December 2023 at the Mayo Clinic in Arizona. Data analysis was performed between February 2024 and June 2024. Outcomes of DBD-SCS, DBD-NMP, DCD-SCS, and DCD-NMP transplants were compared. Exposure DBD and DCD livers preserved on NMP or SCS. Main Outcomes and Measures The primary outcomes were early allograft dysfunction (EAD), intraoperative transfusion, and post-LT hospital resource use, including length of stay (LOS) and readmissions. Secondary outcomes included acute kidney injury (AKI) and 1-year graft and patient survival. Results A total of 1086 LTs were included in the following 4 groups: DBD-SCS (n = 480), DBD-NMP (n = 63), DCD-SCS (n = 264), and DCD-NMP (n = 279). Among LT recipients, median (IQR) age was 60.0 years (52.0-66.0); 399 LT recipients (36.7%) were female. DCD-NMP had the lowest EAD rate (17.5%), followed by DCD-SCS (50.0%), DBD-NMP (36.8%), and DBD-SCS (27.3%) ( P < .001). DCD-NMP had the lowest intraoperative transfusion requirement compared to all other groups. Hospital and intensive care unit (ICU) LOS were shortest in DCD-NMP (median [IQR] hospital LOS, 5.0 days [4.0-7.0]; P = .01; median [IQR] ICU LOS, 1.5 days [1.2-3.1]; P = .01). One-year cumulative readmission probability was 86% lower for DCD-NMP vs DCD-SCS (95% CI, 0.09-0.22; P < .001) and 53% lower for DBD-NMP vs DBD-SCS (95% CI, 0.26-0.87; P < .001). AKI events were lower in DCD-NMP (31.1%) vs DCD-SCS (47.4%) ( P = .001). Compared to SCS, the NMP group had a 78% overall reduction in graft failure (hazard ratio [HR], 0.22; 95% CI, 0.10-0.49; P < .001). For those receiving DCD allografts, the risk reduction was even more pronounced, with an 87% decrease in graft failure (HR, 0.13; 95% CI, 0.05-0.33; P < .001). NMP was significantly protective from patient mortality vs SCS (HR, 0.31; 95% CI, 0.12-0.80; P = .02). Conclusions and Relevance In this observational high-volume cohort study, NMP significantly improved LT clinical outcomes and reduced hospital resource use, especially in DCD allografts. NMP may enhance access to LT by addressing the challenges historically linked with DCD liver use.
Performance of Creatinine and Cystatin-Based Equations on Estimating Measured GFR in People with Hematological and Solid Cancers
Titan, Silvia , Lieske, John C. , Meeusen, Jeffrey W. , Thorson, Stacy , Lin, Yi , Nowakowski, Grzegorz S. , Barreto, Jason N. , Frazee, Erin N. , Ruddy, Kathryn J. , Leung, Nelson , Titan, Silvia M , Frazee, Erin N , Rule, Andrew D , Herrmann, Sandra M , Leung, Nelson , Lieske, John C , Lin, Yi , Thorson, Stacy , Rule, Andrew D. , Herrmann, Sandra M.

Mayo Clinic

Clinical Journal of the American Society of Nephrology | January 28, 2025 | Volume: 20 | Issue: 3 | Pages: 358-366

10.2215/cjn.0000000616 | PMID 39874103 Get It

Key Points Studies on GFR assessment in people with cancer are needed. In this study, the creatinine–cystatin C equations performed better than other equations, and this was observed in solid and hematological cancers. Our findings give support to the preferential use of creatinine and cystatin C–based equations in people with cancer. Background GFR assessment is important in clinical practice with implications for diagnosis, prognostication, and drug dosing. People with cancer are at risk of imprecision in GFR estimation. This cross-sectional study evaluated the performance of various creatinine and cystatin C–based equations in comparison with measured GFR (mGFR) in people with cancer. Methods We retrieved data for all adult patients who had mGFR by urinary iothalamate clearance between 2011 and 2023 at Mayo Clinic and use of an electronic health record diagnosis code for cancer within 2 years before mGFR. The CKD Epidemiology Collaboration (CKD-EPI), European Kidney Function Consortium, and Cockcroft–Gault equations were computed, along with performance metrics (bias, precision, and root mean square error [RMSE]. Confidence intervals were generated by bootstrapping, and analysis were stratified by solid and hematological cancers. Results From all adults with cancer and mGFR, 1145 had both creatinine and cystatin C available within 7 days of mGFR. Among all equations, the creatinine–cystatin C CKD-EPI equation provided the best performance, with small bias (median, 3.0; 95% confidence interval, 2.3 to 3.8) and higher precision (RMSE, 14.5) compared with creatinine-only or cystatin C–only equations (RMSE varying from 16.6 to 20), and this was also true in solid and hematological cancers. The creatinine–cystatin European Kidney Function Consortium equation had a similar performance to CKD-EPI, Cockcroft–Gault showed worst precision (30% of people with errors above 30%), and cystatin C CKD-EPI equation was the most biased, prone to underestimation of mGFR. Conclusions In our cohort of patients with mGFR and cancer, the CKD-EPI creatinine–cystatin C equation performed best for GFR assessment, and this was true for both solid and hematological cancers. Our findings give support for the preferential use of creatinine and cystatin C–based equations instead of creatinine-only or cystatin C–only equations in people with cancer. Podcast This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2025_03_25_CJASNMar20.3.3252025.mp3
CSF cytokine, chemokine and injury biomarker profile of glial fibrillary acidic protein (GFAP) autoimmunity
Segal‬‏, Yahel , Mangioris, Georgios , Lennon, Vanda A. , Yang, Binxia , Dubey, Divyanshu , McKeon, Andrew , Mills, John R. , Tolédano, Michel B. , Vodopivec, Ivana, Pittock, Sean J. , Ζεκερίδου, Αναστασία , Dubey, Divyanshu , Pittock, S J , Lennon, Vanda, McKeon, Andrew , Zekeridou, Anastasia , Dubey, Divyanshu , Yang, Binxia , Flanagan, Eoin P. , Toledano, Michel, Segal, Yahel

Mayo Clinic

Annals of Clinical and Translational Neurology | January 27, 2025 | Volume: 12 | Issue: 4 | Pages: 855-860

10.1002/acn3.52305 | PMID 39869499 Get It

AbstractDefining the CSF cytokine/chemokine and injury biomarker signature of glial fibrillary acidic protein (GFAP) autoimmunity can inform immunopathogenesis. CSF GFAP‐IgG‐positive samples (N = 98) were tested for 17 cytokines/chemokines, neurofilament light chain (NfL), and GFAP (ELLA, Bio‐Techne). Controls included non‐inflammatory (N = 42), AQP4‐IgG‐positive (N = 83), CNS infections (N = 13), and neurosarcoidosis (N = 32). IL5, IL6, IL10, IL8/CXCL8, CXCL9, CXCL10, CXCL13, BAFF, GM‐CSF, IFN‐gamma, and TNF‐alpha concentrations were higher compared to non‐inflammatory controls (P < 0.01). GFAP concentrations were similar to those of AQP4‐IgG‐positive patients; NfL was higher (P < 0.001) and correlated with MRI changes and outcomes. CSF cytokine/chemokine findings in GFAP autoimmunity correlate with histopathology; GFAP and NfL hold promise as disease biomarkers.
Peak part 1 summary: A phase 3, randomized, open-label, multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).
Wagner, Andrew J. , Attia, Steven , Agulnik, Mark , Tap, William D. , Zou, Liangxing, Shah, Nisha , Moynihan, Kevin, Lawrence, Julia, Somaiah, Neeta , Trent, Jonathan C. , Wilky, Breelyn A , Mehren, Margaret von , Davis, Elizabeth J. , Shah, Nisha, Sun, Lei

Mayo Clinic

Journal of Clinical Oncology | January 27, 2025 | Volume: 43 | Issue: 4_suppl | Pages: 826-826

10.1200/jco.2025.43.4_suppl.826 Get It

826 Background: After initial response to first line therapy with imatinib, GISTs commonly progress due to secondary resistance mutations in KIT. As the KIT mutation targeting profiles of bezuclastinib (type I TKI) and sunitinib are distinct, when combined they inhibit a broad spectrum of secondary KIT mutations. Herein we report extended experience of patients treated with 2 nd line combination bezuclastinib and sunitinib, including response assessment and safety. Methods: Peak (NCT05208047), a global randomized Phase 3, open-label study, aims to evaluate efficacy and safety of bezuclastinib + sunitinib vs sunitinib in GIST pts with imatinib intolerance or resistance. In Part 1a of the 3-part study, the dose of an optimized formulation of bezuclastinib was escalated in serial cohorts to achieve a target exposure comparable to that achieved at the RP2D established in the prior Phase 1b/2a study. Part 1b evaluated the interaction between bezuclastinib + sunitinib. Key inclusion: adult with locally advanced, metastatic and/or unresectable GIST, ≥1 measurable lesion according to modified RECIST v1.1, and ECOG PS 0 to 2. Part 1 completed enrollment in Apr 2023. Based upon PK and safety, a dose of bezuclastinib 600 mg QD + sunitinib 37.5 mg QD was selected for Part 2. All Part 1 data reported herein are as of Aug 2023; updated safety and efficacy will be presented. Results: Part 1 has completed enrollment with 19 pts in Part 1a and 23 in 1b. In Part 1a, Cohort 1 included 5 pts starting at bezuclastinib 300 mg QD + sunitinib 37.5 mg QD; Cohort 2 included 14 pts at bezuclastinib 600 mg QD + sunitinib 37.5 mg QD. Pt characteristics in Part 1a+1b: median age - 60 yrs (range: 33-77); 81% men; 98% ECOG PS 0-1; 98% metastatic and 2% locally advanced. The majority of TEAEs were low grade and reversible with low rate (38%) of Grade 3+ events. There were limited (24%) dose reductions and infrequent (n=2) discontinuations due to TEAEs. Three pts experienced serious AEs possibly associated with study medications. In pts evaluable for response (received ≥1 cycle of study treatment and had assessments at baseline and post-baseline [n=40]), the objective response rate (ORR) was 20% (6 confirmed PRs, 2 unconfirmed PRs). Data remain immature to estimate median PFS for Part 1 pts. In a subset of pts with prior imatinib only (n=6), the closest approximation for pts enrolling in Part 2, the ORR was 33% (2 confirmed PRs). The majority of 2nd-line pts remain on treatment past 12 months. Conclusions: Data from Peak Part 1 show an encouraging safety and tolerability profile generally consistent with published sunitinib monotherapy experience. ORR in evaluable pts from Part 1 was 20%; ORR in 2 nd line pts was 33%. Part 2 of the Peak study is actively enrolling pts globally at the selected dose of bezuclastinib 600 mg QD + sunitinib 37.5 mg QD versus sunitinib 37.5 mg QD. Clinical trial information: NCT05208047 .
Clinical outcome after complete response with immunotherapy in hepatocellular carcinoma.
Chen, Pin‐Jung , Kournoutas, Ioannis , Sanford, Alison, Adetyan, Hasmik , Rezaee‐Zavareh, Mohammad Saeid , Ayoub, Walid S. , Kaymen, Emily, Hendifar, Andrew , Yang, Ju Dong , Sanford, Alison, Kim, Naomy , Kuo, Alexander , Kaymen, Emily A. , Tran, Nguyen H. , Yang, Ju Dong

Mayo Clinic

Journal of Clinical Oncology | January 27, 2025 | Volume: 43 | Issue: 4_suppl | Pages: 573-573

10.1200/jco.2025.43.4_suppl.573 Get It

573 Background: Immunotherapy has shown great efficacy in hepatocellular carcinoma (HCC). No clear consensus exists on when to stop the immune checkpoint inhibitor (ICI) after complete response (CR), and clinical course after stopping ICI remains unknown. Methods: We identified 138 HCC patients who received ICI at Cedars-Sinai Medical Center and Mayo Clinic Rochester from 2016-2023. Modified Response Evaluation Criteria In Solid Tumors (mRECIST) was used to assess treatment response. We further described the clinical course of patients who achieved CR after ICI discontinuation, including cancer recurrence, subsequent treatment, liver transplantation (LT) listing and outcomes. Results: The median age at ICI initiation was 68 years; 79% were male; 55.9% were white; 51.5% were BCLC stage C. 9.4% CRs, 25.4% partial responses, 39.9% stable diseases, and 25.4% progressive disease. Hepatitis C etiology was associated with higher likelihood of CR (P=0.005). Among 13 patients who achieved CR, 10 stopped ICI (60% for LT evaluation, 40% for toxicity). After stopping ICI, 40% had recurrence (Table). 3 patients underwent local therapy for recurrent HCC within Milan criteria and 1 patient restarted ICI for recurrence beyond Milan criteria. Among CR patients, 9 patients underwent LT evaluation after stopping ICI and 7 patients were waitlisted. After listing, 3 dropouts were observed, due to recurrent HCC beyond Milan criteria, sepsis leading to death, and personal preference. 4 patients underwent LT. 2 patients underwent local therapy before LT for recurrent HCC (Table). All transplanted patients had the last dose of ICI more than 1 year before LT (12, 21, 24, and 29 months). On explanted livers, 2 patients had no residual viable tumor and 2 patients had residual HCC within Milan criteria. 1 patient developed acute cellular rejection and was treated with immunosuppressants and maintained stable graft function. None had graft loss or evidence of HCC recurrence in the follow-up period at 8, 20, 28, and 51 months. Conclusions: Immunotherapy demonstrated excellent effects on a subset of HCC patients, including 9.4% who achieved CR. After stopping ICI, 40% had cancer recurrence but 3 out of 4 were within Milan criteria. 4 underwent successful LTs (2.9%) with excellent post LT outcome. Larger prospective data is needed to establish a protocol for ICI use, especially to determine the optimal timing for ICI discontinuation after CR. BCLC at ICI initiation ICI cycles before stopping, ICI Recurrence after last ICI (days) Within Milan at recurrence Treatment(s) received after recurrence and outcomes OS (days) Patient 1 B 7, Nivolumab 730 No Nivolumab. Died from GI bleeding 1065 Patient 2 B 64, Atezo/Bev 149 Yes TACE with CR, followed by LT without recurrence. 1203 Patient 3 A 8, Nivolumab 1393 Yes Y90 with CR. No recurrence. 1984 Patient 4 C NA, Pembrolizumab 407 Yes TACE and MWA with CR, followed by LT without recurrence. 1722